EcoDrugPlus

Bcl2 Like 1

Ensembl ID : ENSRFEG00010012421
Gene Symbol: BCL2L1
1 Cross references
286 Possible Orthologues:

Bcl2 Related Protein A1

Ensembl ID : ENSRFEG00010017664
Gene Symbol: BCL2A1
1 Cross references
114 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSRFEG00010013595
Gene Symbol: BCR
1 Cross references
274 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSRFEG00010001196
Gene Symbol: BTK
1 Cross references
207 Possible Orthologues:

C-C Motif Chemokine Receptor 1

Ensembl ID : ENSRFEG00010016979
Gene Symbol: CCR1
1 Cross references
299 Possible Orthologues:

C-C Motif Chemokine Receptor 2

Ensembl ID : ENSRFEG00010016924
Gene Symbol: CCR2
1 Cross references
286 Possible Orthologues:

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSRFEG00010006527
Gene Symbol: CCR4
1 Cross references
254 Possible Orthologues:

C-C Motif Chemokine Receptor 5

Ensembl ID : ENSRFEG00010016913
Gene Symbol: CCR5
1 Cross references
298 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSRFEG00010017112
Gene Symbol: CCR9
1 Cross references
262 Possible Orthologues:

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSRFEG00010019869
Gene Symbol: CXCL8
1 Cross references
183 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSRFEG00010006005
Gene Symbol: CXCR4
1 Cross references
283 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSRFEG00010017672
Gene Symbol: CFTR
1 Cross references
216 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).